The role of atrial natriuretic peptide (ANP) in chronic liver disease.
The role of atrial natriuretic peptide (ANP) and potential defects of ANP in liver disease are reviewed. Patients with cirrhosis of the liver show no decrease of ANP plasma concentrations nor changes in the pattern of ANP immunoreactivity nor changes of splanchnic ANP clearance. The renal effects of exogenously administered as well as endogenously released ANP are blunted in cirrhosis, in particular in patients with ascites. This seems due to increased activity of sodium-retaining hormonal systems and changes of the renal ANP receptor status. Pharmacological inhibition of ANP-degradation or clearance may yield therapeutic potential.
Gerbes
A L
AL
Department of Internal Medicine II, Klinikum Grosshadern, University of Munich, Germany.
D000818:Animals; D009320:Atrial Natriuretic Factor / Q000097:blood / Q000502:physiology* / Q000627:therapeutic use; D002908:Chronic Disease; D006439:Hemodynamics / Q000502:physiology; D006801:Humans; D007668:Kidney / Q000502:physiology; D008102:Liver Circulation / Q000502:physiology; D008107:Liver Diseases / Q000097:blood / Q000188:drug therapy / Q000503:physiopathology*
D009320:Atrial Natriuretic Factor